Phase II Study to Evaluate the Efficacy of Brentuximab Vedotin in Patients With Steroid-Resistant Acute GVHD
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 26 Jun 2013
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Graft-versus-host disease
- Focus Biomarker; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 26 Jun 2013 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 01 Sep 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.